Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development | News
Search Refinements

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
61-75 of 3837 results
DiscoveryBioMed awarded Dual SBIR awards for PKD drug discovery and validation
DiscoveryBioMed learned in recent months that it was awarded a new Phase 1 SBIR grant from the National Institutes of Health (NIH) to perform high-throughput screening (HTS)-based drug discovery and validation to discover novel small molecules that attack the secondary phase of autosomal dominant polycystic kidney disease (ADPKD).
Drug Research > Drug Discovery & Development > News
BrainStorm reports last patient visit in Phase IIa ALS trial
BrainStorm Cell Therapeutics, a leading developer of adult stem cell technologies for neurodegenerative diseases, has announced that the last patient has completed the last visit in its phase 2a clinical trial of NurOwn in Amyotrophic Lateral Sclerosis (ALS), conducted at the Hadassah Medical Center in Jerusalem.
Drug Research > Drug Discovery & Development > News
Eleven Biotherapeutics report top-line results from Phase II trial of EBI-005
Eleven Biotherapeutics, a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, has announced top-line results from a Phase 2 study of its lead drug candidate, EBI-005, in patients with moderate to severe allergic conjunctivitis.
Drug Research > Drug Discovery & Development > News
China Oncology to develop and commercialize Sorrento's anti-PD-L1 antibody
By PBR Staff Writer
Lee's Pharma affiliate China Oncology Focus has secured license from US-based Sorrento Therapeutics for its fully human immune-oncology anti-PD-L1 monoclonal antibody (mAb) STI-A1014.
Drug Research > Drug Discovery & Development > News
Neurocrine begins tourette syndrome clinical trial of NBI-98854
Neurocrine Biosciences has initiated a clinical trial of NBI-98854, a proprietary small molecule Vesicular Monoamine Transporter 2 (VMAT2) inhibitor, in both children and adolescents with Tourette syndrome.
Drug Research > Drug Discovery & Development > News
Regeneron, Sanofi report positive Phase II trial results of dupilumab in CSwNP patients
By PBR Staff Writer
US-based Regeneron Pharmaceuticals and French pharmaceutical firm Sanofi have reported positive results from a Phase IIa proof-of-concept trial of dupilumab in patients with chronic sinusitis with nasal polyps (CSwNP).
Drug Research > Drug Discovery & Development > News
Bristol-Myers Squibb reports positive phase III data for Opdivo in advanced melanoma patients
Bristol-Myers Squibb Company has announced positive results from CheckMate -037, a Phase 3 randomized, controlled open-label study of Opdivo (nivolumab), an investigational PD-1 immune checkpoint inhibitor, versus investigator’s choice chemotherapy (ICC) in patients with advanced melanoma who were previously treated with Yervoy (ipilimumab).
Drug Research > Drug Discovery & Development > News
Kamada announces second extension of strategic agreement with Baxter
Kamada, a plasma-derived protein therapeutics company focused on orphan indications, announced today the second extension to supply Glassia to Baxter in its strategic agreement with the biopharmaceutical business of Baxter International.
Drug Research > Drug Discovery & Development > News
Takeda to invest $25m in drug discovery firm BioMotiv
By PBR Staff Writer
Japanese drug maker Takeda Pharmaceutical is planning to invest $25m in BioMotiv, a drug discovery company associated with The Harrington Project for Discovery & Development.
Drug Research > Drug Discovery & Development > News
Circulomics gets Phase I SBIR to develop nanobind extraction method for FFPE samples
Circulomics has been awarded a Phase I Small Business Innovative Research (SBIR) grant by the National Institutes of Health (NIH) to develop its Nanobind DNA and RNA isolation technology for formalin-fixed, paraffin-embedded (FFPE) samples.
Drug Research > Drug Discovery & Development > News
FibroGen reports one-year data of FG-3019 in patients with Idiopathic Pulmonary Fibrosis
FibroGen has announced the presentation of the full data set from a clinical study of patients with idiopathic pulmonary fibrosis (IPF) treated for 48 weeks with the investigational drug FG-3019.
Drug Research > Drug Discovery & Development > News
Novo Nordisk's Phase IIIb trial of Ryzodeg fails to meet primary endpoint
By PBR Staff Writer
Novo Nordisk has reported results from a 26-week randomized multinational Phase IIIb trial, which showed that Ryzodeg (insulin degludec/insulin aspart) administered twice daily, provides successful glycaemic control with fewer injections than a basal-bolus regimen.
Drug Research > Drug Discovery & Development > News
Boehringer, CureVac to develop next generation lung cancer immunotherapy
By PBR Staff Writer
Boehringer Ingelheim has entered into an exclusive global license and development agreement with CureVac to develop the latter's new investigational therapeutic mRNA vaccine CV9202 to treat lung cancer.
Drug Research > Drug Discovery & Development > News
Lupin and Merck Serono enter into strategic alliance
By PBR Staff Writer
Lupin and Merck Serono have entered into a strategic partnership to support the latter to broaden its general medicines portfolio in emerging markets.
Drug Research > Drug Discovery & Development > News
Cardiorentis announces €45m financing with HealthCare Royalty Partners
By PBR Staff Writer
Cardiorentis AG, a privately held biopharmaceutical company, announced that it has entered into a €45m financing agreement with HealthCare Royalty Partners (HC Royalty), a US based healthcare investment firm.
Drug Research > Drug Discovery & Development > News
61-75 of 3837 results